Matching articles for "elbasvir"
Issue 1714 · October 28, 2024
Drugs for Hepatitis C Virus Infection

About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA)…

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):169-74 doi:10.58347/tml.2024.1714a
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Issue 1714 · October 28, 2024
Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults (online only)

View Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):e174 doi:10.58347/tml.2024.1714e
View Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults
Issue 1714 · October 28, 2024
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)

View Table 3: Some Drug Interactions with DAAs for HCV Infection

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):e175 doi:10.58347/tml.2024.1714f
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Issue 1531 · October 9, 2017
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection

The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of…

Med Lett Drugs Ther. 2017 Oct 9; 59(1531):166-70
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.
Issue 1506 · October 24, 2016 Free
In Brief: Hepatitis B Reactivation with Direct-Acting Antiviral Drugs for Hepatitis C

The FDA recently announced that it will require the labeling of all direct-acting antiviral drugs used for treatment of hepatitis C virus (HCV) infection to include a boxed warning about a risk of hepatitis B…

Med Lett Drugs Ther. 2016 Oct 24; 58(1506):140
The FDA recently announced that it will require the labeling of all direct-acting antiviral drugs used for treatment of hepatitis C virus (HCV) infection to include a boxed warning about a risk of hepatitis B virus (HBV) reactivation associated with their use. 1 Twenty-four cases of HBV reactivation occurring during treatment with direct-acting antiviral drugs for HCV were identified from the FDA Adverse Event Reporting System and the medical literature. 2-5 Before starting direct-acting antiviral treatment for HCV, some of these patients were hepatitis B surface antigen (HbsAG) positive and others showed evidence of resolved HBV infection. HBV reactivation generally occurred within 4-8 weeks of starting treatment. Reactivation of HBV can cause increases in bilirubin and aminotransferase levels, fulminant hepatitis, hepatic failure, and death. Of the 24 patients, two died and one required a liver transplant. HBV reactivation was not identified before FDA approval of these drugs because the clinical trials used to support their approval excluded patients with HBV co-infection. The mechanism by which HBV reactivation occurs during treatment with direct-acting antiviral drugs for HCV is unknown. Patients should be screened for current or past HBV infection before starting treatment with a direct-acting antiviral and monitored for HBV reactivation during and following treatment with these drugs. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Available at: www.fda.gov. Accessed October 13, 2016. JM Collins et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015; 61:1304. A De Monte et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016; 78:27. AR Ende et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015; 9:164. C Wang et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2016 July 5 (epub). Download complete U.S. English article
Issue 1501 · August 15, 2016
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection.…

Med Lett Drugs Ther. 2016 Aug 15; 58(1501):107-8
The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
Issue 1489 · February 29, 2016
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of…

Med Lett Drugs Ther. 2016 Feb 29; 58(1489):25-7
The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.